Abstract:Objective: Systemic sclerosis-associated interstitial lung disease (SSc-ILD) is the leading cause of death in patients with SSc with unclear pathogenesis and limited treatment options. Evidence strongly supports an important role for profibrotic secreted phosphoprotein 1 (SPP1)-expressing macrophages in SSc-ILD. This study was undertaken to define the transcriptome and chromatin structural changes of SPP1 SSc-ILD macrophages in order to better understand their role in promoting fibrosis and to identify transcription factors associated with open chromatin driving their altered phenotype. Methods: We performed single-cell RNA sequencing (scRNA-Seq) on 11 explanted SSc-ILD and healthy control lung samples, as well as single-cell assay for transposase-accessible chromatin sequencing on 5 lung samples to define altered chromatin accessibility of SPP1 macrophages. We predicted transcription factors regulating SPP1 macrophages using single-cell regulatory network inference and clustering (SCENIC) and determined transcription factor binding sites associated with global alterations in SPP1 chromatin accessibility using Signac/Seurat. Results: We identified distinct macrophage subpopulations using scRNA-Seq analysis in healthy and SSc-ILD lungs and assessed gene expression changes during the change of healthy control macrophages into SPP1 macrophages. Analysis of open chromatin validated SCENIC predictions, indicating that microphthalmia-associated transcription factor, transcription factor EB, activating transcription factor 6, sterol regulatory element binding transcription factor 1, basic helix-loop-helix family member E40, Kruppel-like factor 6, ETS variant transcription factor 5, and/or members of the activator protein 1 family of transcription factors regulate SPP1 macrophage differentiation. Conclusion: Our findings shed light on the underlying changes in chromatin structure and transcription factor regulation of profibrotic SPP1 macrophages in SSc-ILD. Similar alterations in SPP1 macrophages may underpin fibrosis in other organs involved in SSc and point to novel targets for the treatment of SSc-ILD, specifically targeting profibrotic macrophages.

Advances in epigenetics in systemic sclerosis: molecular mechanisms and therapeutic potential

Role of Epigenetics in the Pathogenesis of Systemic Sclerosis

Research Progress in Epigenetic Studies on Systemic Sclerosis

The Epigenetic Regulation of Scleroderma and Its Clinical Application

Pathogenic Roles of Autoantibodies and Aberrant Epigenetic Regulation of Immune and Connective Tissue Cells in the Tissue Fibrosis of Patients with Systemic Sclerosis

Unfolding the Pathogenesis of Systemic Sclerosis Through Epigenomics

Systemic Sclerosis: Genetics and Epigenetics

Molecular Mechanisms, Pathogenetic Role and Therapeutic Opportunities

The contribution of epigenetics to the pathogenesis and gender dimorphism of systemic sclerosis: a comprehensive overview

Emerging therapeutic targets in systemic sclerosis

Recent Insights into the Role of DNA Methylation and Histone Modifications in Systemic Sclerosis: A Scoping Review

Immune Cell Dysregulation As a Mediator of Fibrosis in Systemic Sclerosis

Understanding Fibrosis in Systemic Sclerosis: Novel and Emerging Treatment Approaches

Genome‐wide integrated DNA methylome and transcriptome analysis reveals a strong dysregulated myeloid component in the epigenetic landscape of Systemic Sclerosis

Systematic Approach to Understanding the Pathogenesis of Systemic Sclerosis

Distinct Metalloproteinase Expression and Functions in Systemic Sclerosis and Fibrosis: What We Know and the Potential for Intervention

Current Concepts on the Pathogenesis of Systemic Sclerosis

Targeting cytokines and potentiality of JAK–STAT inhibition in systemic sclerosis

Emerging drugs and therapeutics for systemic sclerosis

Epigenetic Regulation of Profibrotic Macrophages in Systemic Sclerosis-Associated Interstitial Lung Disease

The role of extracellular matrix components in angiogenesis and fibrosis: Possible implication for Systemic Sclerosis